Keywords: Eli lilly
The American healthcare company CVS Health has announced that it will reinstate insurance coverage for Eli Lilly’s obesity treatment Zepbound, marking a significant shift in its pharmacy benefit policies. The decision was made by CVS Caremark, the company’s pharmacy benefit management division,......
France is set to begin reimbursing weight-loss medications for severely obese patients starting in mid-June, according to Health Minister Stéphanie Rist. The decision marks a significant step in the country’s public health strategy to address rising obesity rates and improve access to modern......
The Supreme Court of the United States has refused to hear a legal challenge brought by Eli Lilly and Company against a historic whistleblower law that allows private citizens to file fraud lawsuits on behalf of the federal government. The decision leaves in place a lower court ruling ordering the pharmaceutical......
Eli Lilly and Company has announced a new $4.5 billion investment in its manufacturing operations in the state of Indiana, reinforcing its long-term commitment to expanding production capacity in the United States. Major expansion in Indiana The additional funding will be allocated across two of the......
Eli Lilly and Company has announced an agreement to acquire the privately held biotechnology firm Ajax Therapeutics in a deal valued at up to $2.3 billion in cash. The move strengthens Lilly’s position in the oncology sector, particularly in the development of treatments for rare blood cancers. Ajax......
The Eli Lilly and Co weight-loss pill has received approval from the U.S. Food and Drug Administration, marking a major step in the growing market for oral obesity treatments. The drug, called orforglipron and marketed under the brand name Foundayo, becomes the second pill-based option available in the......
Eli Lilly said its experimental drug retatrutide met all primary and secondary endpoints in a phase 3 clinical trial for type 2 diabetes, delivering significant reductions in blood sugar and body weight over 40 weeks. The TRANSCEND-T2D-1 trial involved 537 adults whose diabetes was not adequately controlled......
-
15:46
-
15:31
-
15:31
-
15:15
-
15:11
-
15:01
-
15:00
-
14:42
-
14:25
-
14:10
-
13:58
-
13:57
-
13:47
-
13:31
-
13:20
-
13:15
-
13:10
-
13:00
-
12:42
-
12:25
-
12:10
-
11:47
-
11:32
-
11:15
-
11:14
-
11:00
-
10:42
-
10:21
-
10:15
-
10:05
-
09:45
-
09:32
-
09:15
-
09:00
-
08:43
-
08:25
-
08:10
-
07:59
-
07:55
-
07:47
-
07:46
-
07:35
-
07:31
-
07:30
-
07:28
-
07:17
-
07:17
-
07:15
-
20:00
-
19:21
-
19:05
-
18:45
-
18:30
-
18:15
-
18:00
-
17:43
-
17:25
-
17:10
-
16:45
-
16:26
-
16:12
-
16:10
-
16:02
-
15:50
-
15:47
